Recursion Pharmaceuticals is trading at $4.60, up 5.50% in pre-market on October 12, with no clear company-specific catalyst identified. - The latest company-news scan lists no October 12 news; an October 9 after-hours item described a recovery but gave no cause. - Recursion Pharmaceuticals rose 10.38% to $4.36 on October 9 amid biotech-sector strength, but that earlier session does not explain this move. - Broad-market gains were modest and do not clearly explain the pre-market advance.